Literature DB >> 10845804

Framing of outcome and probability of recurrence: breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios.

C Zimmermann1, C Baldo, A Molino.   

Abstract

PURPOSE: To examine the effects of framing of outcome and probabilities of cancer occurrence on the treatment preference which breast cancer patients indicate for hypothetical patient scenarios.
METHODS: A modified version of the Decision Board Instrument (Levine et al. 1992) was administered to 35 breast cancer patients with past ACT experience. Patients expressed their choice regarding ACT for six scenarios which were characterized by either negative or positive framing of outcome and by one of the three levels of probability of recurrence (high, medium, low).
RESULTS: The framing had no influence on ACT choices over all three probability levels. The majority chose ACT for high and medium risk and one third switched from ACT to No ACT in the low-risk condition. This switch was statistically significant.
CONCLUSION: Hypothetical treatment decisions against ACT occur only when the probability of recurrence is low and the benefit of ACT is small. This finding for patients with past experience of ACT is similar to those reported for other oncological patient groups still in treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10845804     DOI: 10.1023/a:1006342316373

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

Authors:  John Hornberger; Rebecca Chien; Katie Krebs; Louis Hochheiser
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  Effect of endurance for adverse drug reactions on the preference for aggressive treatments in cancer patients.

Authors:  Naomi Iihara; Takayuki Nishio; Tetsuko Goda; Hideaki Anzai; Masatoshi Kagawa; Hitoshi Houchi; Yutaka Kirino
Journal:  Support Care Cancer       Date:  2014-10-08       Impact factor: 3.603

3.  Survival benefit needed to undergo chemotherapy: Patient and physician preferences.

Authors:  Ines Vaz-Luis; Anne O'Neill; Karen Sepucha; Kathy D Miller; Emily Baker; Chau T Dang; Donald W Northfelt; Eric P Winer; George W Sledge; Bryan Schneider; Ann H Partridge
Journal:  Cancer       Date:  2017-03-21       Impact factor: 6.860

4.  Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.

Authors:  Jeanne S Mandelblatt; Vanessa B Sheppard; Arti Hurria; Gretchen Kimmick; Claudine Isaacs; Kathryn L Taylor; Alice B Kornblith; Anne-Michelle Noone; Gheorghe Luta; Michelle Tallarico; William T Barry; Lisa Hunegs; Robin Zon; Michael Naughton; Eric Winer; Clifford Hudis; Stephen B Edge; Harvey Jay Cohen; Hyman Muss
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Positive Attribute Framing Increases COVID-19 Booster Vaccine Intention for Unfamiliar Vaccines.

Authors:  Kirsten Barnes; Ben Colagiuri
Journal:  Vaccines (Basel)       Date:  2022-06-16

Review 6.  Describing treatment effects to patients.

Authors:  Annette Moxey; Dianne O'Connell; Patricia McGettigan; David Henry
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

7.  Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study.

Authors:  Rachel C Shelton; Grace Clarke Hillyer; Dawn L Hershman; Nicole Leoce; Dana H Bovbjerg; Jeanne S Mandelblatt; Lawrence H Kushi; Lois Lamerato; S David Nathanson; Christine B Ambrosone; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2012-12-22       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.